244 related articles for article (PubMed ID: 19545563)
1. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
3. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
4. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
Muthane U; Ramsay KA; Jiang H; Jackson-Lewis V; Donaldson D; Fernando S; Ferreira M; Przedborski S
Exp Neurol; 1994 Apr; 126(2):195-204. PubMed ID: 7925820
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
[TBL] [Abstract][Full Text] [Related]
6. Creatine and cyclocreatine attenuate MPTP neurotoxicity.
Matthews RT; Ferrante RJ; Klivenyi P; Yang L; Klein AM; Mueller G; Kaddurah-Daouk R; Beal MF
Exp Neurol; 1999 May; 157(1):142-9. PubMed ID: 10222117
[TBL] [Abstract][Full Text] [Related]
7. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP.
Walters TL; Irwin I; Delfani K; Langston JW; Janson AM
Exp Neurol; 1999 Mar; 156(1):62-70. PubMed ID: 10192777
[TBL] [Abstract][Full Text] [Related]
8. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
Zuddas A; Fascetti F; Corsini GU; Piccardi MP
Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
[TBL] [Abstract][Full Text] [Related]
9. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice.
Dluzen DE
Brain Res; 1996 Apr; 715(1-2):113-8. PubMed ID: 8739629
[TBL] [Abstract][Full Text] [Related]
10. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter.
Bezard E; Gross CE; Fournier MC; Dovero S; Bloch B; Jaber M
Exp Neurol; 1999 Feb; 155(2):268-73. PubMed ID: 10072302
[TBL] [Abstract][Full Text] [Related]
11. Methamphetamine- and 1-methyl-4-phenyl- 1,2,3, 6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice.
Itzhak Y; Martin JL; Ali SF
Synapse; 1999 Dec; 34(4):305-12. PubMed ID: 10529724
[TBL] [Abstract][Full Text] [Related]
12. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Teismann P; Ferger B
Synapse; 2001 Feb; 39(2):167-74. PubMed ID: 11180504
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
15. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium.
Giovanni A; Sonsalla PK; Heikkila RE
J Pharmacol Exp Ther; 1994 Sep; 270(3):1008-14. PubMed ID: 7932148
[TBL] [Abstract][Full Text] [Related]
16. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice.
Chan P; Di Monte DA; Langston JW; Janson AM
J Pharmacol Exp Ther; 1997 Jan; 280(1):439-46. PubMed ID: 8996226
[TBL] [Abstract][Full Text] [Related]
17. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels.
Ali SF; David SN; Newport GD; Cadet JL; Slikker W
Synapse; 1994 Sep; 18(1):27-34. PubMed ID: 7825121
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
[TBL] [Abstract][Full Text] [Related]
19. Lack of involvement of glutamate-induced excitotoxicity in MPP+ toxicity in striatal dopaminergic terminals: possible involvement of ascorbate.
Matarredona ER; Santiago M; Machado A; Cano J
Br J Pharmacol; 1997 Jul; 121(5):1038-44. PubMed ID: 9222565
[TBL] [Abstract][Full Text] [Related]
20. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]